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Abstract
Background: A single sampled faecal immunochemical test (FIT) has moderate sensitivity for colorectal cancer and
advanced adenomas. Repeated FIT sampling could improve test sensitivity. The aim of the present study is to
determine whether any of three different strategies of double FIT sampling has a better combination of sensitivity
and specificity than single FIT sampling.
Methods: Test performance of single FIT sampling in subjects scheduled for colonoscopy was compared to double
FIT sampling intra-individually. Test positivity of double FIT sampling was evaluated in three different ways: 1) “one
of two FITs+” when at least one out of two measurements exceeded the cut-off value, 2) “two of two FITs+” when
both measurements exceeded the cut-off value, 3) “mean of two FITs+” when the geometric mean of two FITs
exceeded the cut-off value. Receiver operator curves were calculated and sensitivity of single and the three
strategies of double FIT sampling were compared at a fixed level of specificity.
Results: In 124 of 1096 subjects, screen relevant neoplasia (SRN) were found (i.e. early stage CRC or advanced
adenomas). At any cut-off, “two of two FITs+” resulted in the lowest and “one of two FITs+” in the highest
sensitivity for SRN (range 35-44% and 42%-54% respectively). ROC’s of double FIT sampling were similar to single
FIT sampling. At specificities of 85/90/95%, sensitivity of any double FIT sampling strategy did not differ significantly
from single FIT (p-values 0.07-1).
Conclusion: At any cut off, “one of two FITs+” is the most sensitive double FIT sampling strategy. However, at a given
specificity level, sensitivity of any double FIT sampling strategy for SRN is comparable to single FIT sampling at a different
cut-off value. None of the double FIT strategies has a superior combination of sensitivity and specificity over single FIT.
Background
In the United States of America and in Europe, colorectal
cancer (CRC) ranks second as cause of cancer related
death [1,2]. Screening is the most realistic approach to
decrease CRC related mortality. Screening with guaiac-
based faecal occult blood tests (g-FOBTs) has been shown
to decrease disease specific mortality [3-5]. Faecal immu-
nochemical tests (FITs or i-FOBTs) have been shown to
be superior to g-FOBTs [6-9]. A major benefit of (semi-)
quantitative FITs is that by adjustment of the threshold
for positivity, test characteristics and number of follow-up
colonoscopies can be tuned to local resources [10,11].
Since sensitivity of FIT for CRC is in the range of 66-87%
[8,12,13], and sensitivity for advanced adenomas is even
lower (27-38% depending on the cut-off value) [8,13,14],
there is still room for improvement. One approach for
improving the sensitivity of FIT based screening could be
* Correspondence: f.oort@vumc.nl; s.vanturenhout@vumc.nl
† Contributed equally
1Gastroenterology and Hepatology, VU University Medical Centre, De
Boelelaan 1118, Amsterdam, The Netherlands
Full list of author information is available at the end of the article
Oort et al. BMC Cancer 2011, 11:434
http://www.biomedcentral.com/1471-2407/11/434
© 2011 Oort et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.to increase the number of samples tested, which is com-
mon practice for gFOBTs [3-5].
So far, most studies on double FIT sampling either did
not perform colonoscopy in FIT negative individuals
[15,16], did not evaluate different definitions of positivity
for double FIT sampling [14,17,19], or did not assess the
effect of different cut-off values [17,20]. In addition, none
of these studies evaluated the effect of multiple sampling
on specificity.
This prospective, multi-centre cohort study aims to
investigate whether sensitivity for the detection of screen
relevant neoplasia (CRC stage I, II or advanced adeno-
mas) of single FIT sampling can be increased by double
FIT sampling, without substantially affecting specificity.
Primary goal is to compare sensitivity and specificity of
single FIT sampling and different strategies of double
FIT sampling, at a predefined range of cut-off values, in a
colonoscopy controlled population. In this study, we
report that double and single FIT sampling have a com-
parable combination of sensitivity and specificity, at a dif-
ferent cut-off value.
Methods
Study population
From June 2008 to October 2009, all ambulatory patients
(≥18 years) scheduled for elective colonoscopy in three
participating medical centres in and around Amsterdam,
were invited to participate in this study irrespective of
their indication for colonoscopy (i.e. screening, surveil-
lance, or presence of symptoms). Exclusion criteria were
either hospitalization, age below 18 years, colostomy,
total colectomy, colitis with ulcer(s), or a documented
history or subsequent diagnosis of inflammatory bowel
disease (IBD). In addition, individuals in which colono-
scopic examination remained incomplete due to insuffi-
cient bowel lavage or technical difficulties, who did not
adhere to the instructions on FIT sampling (e.g. failed to
provide the dates of FIT sampling), or could not provide
informed consent, were excluded from analysis. The local
M e d i c a lE t h i c sR e v i e wB o a r d so fe a c ho ft h eh o s p i t a l s
approved this study.
Study design
All eligible individuals were asked to perform a FIT on
two subsequent days prior to colonoscopy. Elective
patients were invited to participate in this study by tele-
phone. Individuals interested in the study received a
more detailed information package by mail, including
two FITs, sampling instructions and an informed consent
form. Subjects who could repetitively not be reached by
telephone were send the same package with an additional
explanatory letter.
An automated FIT was used (OC-sensor
®,E i k e nC h e m i -
cal Co., Tokyo, Japan). This semi-quantitative test is
considered positive when the haemoglobin concentration
in the test tube exceeds the pre-determined cut-off value.
Patients were instructed to perform this test on two sepa-
rate days, before bowel preparation by laxatives was
started, and write the date of performance on the FIT
container.
The baseline FIT was defined as the sample taken from
a bowel movement one day prior to colonoscopy (t = -1),
whereas the additional FIT for double sampling was per-
formed on stool produced two days before colonoscopy
(t = -2; see Figure 1). Illustrated and written instructions
explained participants to sample their stool without con-
tamination with water or urine. All FITs were sampled at
home and there were no restrictions in diet or medica-
tion during the week in which stool was sampled. Partici-
pants were instructed to obtain FIT samples at a
maximum of 72 hours prior to colonoscopy, and to put
the FIT samples in the zip lock bags that were included
in the mail package. Participants were requested to store
the zip lock bags in the refrigerator until departure for
the endoscopy department.
Completed FITs and informed consent forms were col-
lected at the endoscopy-department at the day of colono-
scopy. All FITs were stored at minus 20 degrees Celsius
on arrival. Tests were analyzed according to the manu-
facturer’s instructions by an experienced technician, who
was unaware of the clinical data, using the OC sensor
MICRO desktop analyzer (Eiken Chemical co., Tokyo,
Japan) [21].
Colonoscopy and lesions
All colonoscopies were performed or supervised by
experienced gastroenterologists, who were unaware of
the FIT results. Patients were offered to take conscious
sedation by Midazolam. A complete colonoscopy was
defined as intubation of the caecum with identification of
the ileocaecal valve or appendiceal orifice, or intubation
up to CRC (irrespective of the location and visualisation
of the whole colon). Incomplete colonoscopies or colo-
noscopies with insufficient bowel preparation, as judged
by the individual endoscopist, were excluded unless CRC
was found. However, if a barium enema, virtual colono-
graphy or second colonoscopy was performed within six
months, evaluation of the colon was considered complete
and the subject was included in analysis. Patients were
classified based on the most advanced lesion detected.
Histology of tissue samples obtained was evaluated
routinely. Lesion size was estimated by the endoscopist.
Adenomas ≥1.0 cm, adenomas with a villous component
(i.e. tubulovillous or villous adenoma) or adenomas with
high-grade dysplasia were defined as advanced adenomas
[22]. Colorectal carcinoma was staged according to the
AJCC cancer and TNM staging manual [23]. Screen
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and/or early stage cancer (i.e. stage I and II).
Statistical analysis
Primary outcome measures were sensitivity and specifi-
city of the baseline FIT (t = -1; henceforth single FIT)
and three strategies for double FIT sampling (results of
t = -1 and t = -2) for the detection of screen relevant
neoplasia. Results of single and double sampling were
compared intra-individually and colonoscopy and histo-
pathology were considered as gold standard. This study
did not have the intention to determine the cut-off
value with optimal sensitivity and specificity for screen-
ing. Instead, we evaluated whether a combination of
sensitivity and specificity for double FIT sampling exists
that is superior to single FIT sampling.
Three different strategies for positive reading of dou-
ble FIT sampling were used:
1. “one of two FITs+": haemoglobin concentrations
e x c e e dt h ec u t - o f fv a l u ei na tl e a s to n eo u to ft w o
samples.
2. “two of two FITs+": haemoglobin concentrations
exceed the cut-off value in both samples.
3. “mean of two FITs+": the geometric mean of hae-
moglobin concentrations from both samples exceeds
the cut-off value.
Test sensitivities and specificities were assessed at cut-
off values of 50, 75, 100, 150, and 200 ng/ml. The Exact
method was used to calculate 95% confidence intervals.
Receiver operator curves (ROC’s) for detecting screen
relevant neoplasia were calculated for single FIT and all
three strategies of double FIT sampling. In addition,
sensitivities of all three strategies for double FIT sam-
pling were compared to single FIT sampling at a specifi-
city of 85%, 90% and 95% using McNemar’st e s tf o r
Figure 1 Study design. FIT = faecal immunochemical test.
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with SPSS for Windows Version 15.0 (SPSS Inc., Chi-
cago, USA).
Results
Participants
Samples were returned by 1589 patients, 493 of which
were excluded from further analysis because of reasons
listed in Figure 2. In 33 cases repeated colonoscopy or
radiology was performed. Mean age of the participants
included was 60, 0 years (range 19-91 yrs, SD 12.5) and
48% of the study cohort was male.
Table 1 shows the primary indications for colonoscopy in
individuals eligible for analysis. In this cohort 59% (N =
646) of individuals were referred for colonoscopy because
of symptoms, whereas 37% (N = 408) of subjects were
referred for screening or surveillance colonoscopy. In 4%
(N = 42) of all individuals the indication remained
unspecified.
Colonoscopy results
Colorectal cancer was found in 35 (3, 2%) of 1096 included
individuals. Malignancies were classified as stage I in 7
(20%), stage II in 13 (37%), stage III in 6 (17%) and stage
IV in 3 (9%) patients. Six rectal cancers (17%) could not be
staged accurately due to the effects of preoperative radia-
tion. In 104 (9, 5%) individuals, one or more advanced
adenomas were found. Consequently, screen relevant neo-
plasia were found in 124 (11, 3%) subjects.
Colorectal neoplasia detection and positivity rates
At a cut-off value of 50 ng/ml, the positivity rate of single
FIT was 17%, resulting in detection of 91, 4% (32/35) of
CRCs and 60, 6% (63/104) of all advanced adenomas
found at colonoscopy. In subjects who tested negative for
occult blood on single FIT, the additional FIT detected 2
more CRCs and 7 additional advanced adenomas.
Positivity rates ranged from 17-10% (with increasing cut-
off values) for single FIT, from 22-12% for “one of two
FITs+”, from 12-7% for “two of two FITs+”, and from 17-
9% for “mean of two FITs+”.
Sensitivity and specificity of single and double FIT
strategies
Performance characteristics of single FIT and different
strategies of double FIT sampling for detecting screen
Figure 2 Study flow diagram of 1589 subjects who participated in FIT sampling and subsequently underwent colonoscopy.
¹Incomplete colon evaluation in spite of possible additional evaluation by repeated colonoscopy, barium enema or virtual colonography. FIT =
faecal immunochemical test, IBD = inflammatory bowel disease.
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in table 2.
At each cut-off value, maximum sensitivity for screen
relevant neoplasia was obtained with “one of two FITs+”.
Compared to single FIT, the highest increase in sensitiv-
ity was obtained with “one of two FITs+” at either 50, 75
or 100 ng/ml (6.4% increase over single FIT). However,
the confidence intervals of the sensitivity of single FIT
and “one of two FITs+” overlapped, and the specificity of
“one of two FITs+” (83.0, 87.4 and 89.8% at 50, 75, and
100 ng/ml, respectively) was lower than for single FIT
(88.2, 90.5, and 92.5% at 50, 75, and 100 ng/ml,
respectively).
At each cut-off value, maximum specificity was found
with “two of two FITs+”. The highest specificity (97, 5%)
of all double FIT strategies was observed for “two of two
FITs+” at the highest cut-off value (200 ng/ml). However,
“two of two FITs+” resulted in lower sensitivities than sin-
gle FIT. Moreover, by using single FIT, comparable speci-
ficities as for “two of two FITs+” could be reached (up to
95%) by using higher cut-off values (see table 2).
Test characteristics of double FIT sampling strategies
were comparable to single FIT sampling at a different
cut-off value. For example at 75 ng/ml, the sensitivity of
“one of two FITs+” (52%) was higher than the sensitivity
of single FIT (46%). However, when the cut-off value of
single FIT was decreased to 50 ng/ml, sensitivity became
48% (CI 39-57) which is close to sensitivity of “one of
two FITs+” (52%; CI 43-61). The accompanying specifi-
city of single FIT at 50 ng/ml (88, 2%) was virtually
equivalent to the specificity of “one of two FITs+” (87,
4%). As shown in table 2, test characteristics of “mean of
two FITs+” were comparable to single FIT.
Receiver operator curves
For single FIT and the three double FIT strategies, ROC’s
were constructed (see Figure 3). Highest sensitivities
were reached with “one of two FITs+” and “mean of two
FITs+”, whereas the highest specificities were reached
with “two of two FITs+”. For all double FIT strategies,
ROC’s and area under the curves (AUC’s) either over-
lapped or were very close to each other (see Figure 3).
Although the highest AUC was found for “mean of two
FITs+”,a l lA U C ’s were within the 95% confidence inter-
val of the AUC of single FIT.
Comparison at fixed specificities
To evaluate to what extent an increase in sensitivity by
double FIT sampling went at the cost of decreased speci-
ficity, single FIT and the three double FIT strategies were
analyzed at equal specificities. Table 3 shows cut-off
values and sensitivities at 85%, 90% and 95% specificity,
for each strategy. At any of these specificities, no strategy
Table 1 Primary indications for colonoscopy among 1096 consecutive patients enrolled for evaluation of double FIT
sampling
Indication Group
Symptomatic/suspect
Indication for colonoscopy N
Weight loss 11
Clinical suspicion of diverticulitis 7
Clinical suspicion of IBD 8
Abdominal pain 110
Anaemia 71
Hematochezia 156
Altered bowel habits 182
Clinical or radiological suspicion of CRC 25
Colonoscopy for polypectomy 21
Diarrhoea 31
Constipation 24
Total 646
Screening & Surveillance Average risk 39
Familial history of CRC 111
Lynch syndrome 17
Polyp surveillance 196
Post CRC surveillance 45
Total 408
Other Not specified/others 42
Grand total 1096
FIT = faecal immunochemical test, IBD = inflammatory bowel disease, CRC = colorectal cancer
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significantly from the sensitivity of single FIT.
Additional analysis
All analyses described above were repeated for the out-
comes advanced adenomas and CRC. Results are shown in
additional file 1: tables S1-S4 and additional file 1: figures
S1 and S2. The results found were very similar to those
for screen relevant neoplasia.
In total 251 cases were excluded because of an error in
FIT sampling. The majority of 155 cases was excluded as
the date of sampling of one or both of the tests was
unsure. These cases were included in additional analysis,
to evaluate if exclusion of these cases would cause bias.
As shown in the Additional file 1, the results of these
analysis were similar. The remaining 96 sampling errors
were due to sampling on or after the day of colonoscopy,
performance of only one test, or failure in FIT analysis.
Discussion
In the present study three different strategies of double
FIT sampling were compared to single FIT sampling. In
total, 1096 subjects were included and evaluated by colo-
noscopy. None of the double FIT strategies proved to have
a superior combination of sensitivity and specificity com-
pared to single FIT sampling, as is clear from the compar-
able ROC’s and similar AUC’sf o u n df o ra l ls t r a t e g i e s .
When comparing sensitivities of single FIT and the three
double FIT strategies at fixed specificities of 85%, 90% and
95%, no relevant differences were observed. In fact, at
every level of specificity, a comparable sensitivity as
observed for “one of two FITs+” could be obtained by sin-
gle FIT by simply lowering the cut off value.
A priori expectations were that double FIT sampling
would increase sensitivity, as this has been observed pre-
viously for g-FOBT and FIT [18,19,24]. Accordingly, it
was shown in the present study that the highest sensitiv-
ity was obtained for ‘’one of two FITs+’’. However, this
strategy resulted in the lowest specificity.
Our findings are in line with a recent study in a popula-
tion with an increased risk for CRC, in which AUC’sf o r
the highest out of one, two or three FITs did not differ
[18]. Although a direct comparison with a recent Italian
screening study is difficult due to different methodology,
the authors could also not find a clear superior perfor-
mance of double over single FIT sampling either [15].
Two other studies on double FIT sampling lacked calcula-
tion of direct sensitivity and specificity, as colonoscopy
was not performed in FIT negative individuals [15,16].
These characteristics are needed to determine how an
increase in sensitivity is counterbalanced by a decrease in
specificity. Less recent studies did not use quantitative
FITs or did not evaluate test characteristics at different
cut-off values [17,20]. In a recent study with a high CRC
prevalence, average risk individuals sampled stool before
screening colonoscopy. The authors found that the sensi-
tivity increased and specificity decreased when a lower
cut-off value or multiple tests were used. However, no
Table 2 Test characteristics of single and double FIT sampling for detection of screen relevant neoplasia
Single FIT “one of two FITs+”“ two of two FITs+”“ mean of two FITs+”
Cut-off value Sens Spec Sens Spec Sens Spec Sens Spec
Cut-off 50 47, 6% 88, 2% 54, 0% 83, 0% 43, 5% 93, 2% 52, 4% 88, 8%
N 59/124 844/957 67/124 794/957 54/124 892/957 65/124 850/957
(CI) (39-57) (86-90) (45-63) (80-85) (35-53) (91-95) (43-61) (87-91)
Cut-off 75 46, 0% 90, 5% 52, 4% 87, 4% 41, 1% 94, 4% 46, 8% 91, 3%
N 57/124 866/957 65/124 836/957 51/124 903/957 58/124 874/957
(CI) (37-55) (88-92) (43-61) (85-89) (32-50) (93-96) (38-56) (89-93)
Cut-off 100 45, 2% 92, 5% 51, 6% 89, 8% 39, 5% 95, 5% 44, 4% 92, 8%
N 56/124 885/957 64/124 859/957 49/124 914/957 55/124 888/957
(CI) (36-54) (91-94) (42-61) (88-92) (31-49) (94-9s7) (35-54) (91-94)
Cut-off 150 42, 7% 94, 6% 47, 6% 92, 2% 35, 5% 96, 8% 38, 7% 94, 1%
N 53/124 905/957 59/124 882/957 44/124 926/957 48/124 901/957
(CI) (34-52) (93-96) (39-57) (89-93) (27-45) (95-98) (30-48) (92-96)
Cut-off 200 37, 9% 95, 1% 41, 9% 93, 2% 34, 7% 97, 5% 37, 1% 96, 1%
N 47/124 910/957 52/124 892/957 43/124 933/957 46/124 920/957
(CI) (29-47) (94-96) (39-57) (91-95) (26-44) (96-98) (29-46) (95-97)
Test characteristics at different cut-off values (ng/ml) of single and three strategies of double FIT sampling for detection of screen relevant neoplasia in 1081*
individuals referred for colonoscopy (SRN in 124, no AA nor CRC in 957). *15 cases of late stage CRC were excluded since they were not considered screen
relevant.
FIT = faecal immunochemical test, SRN = screen relevant neoplasia, AA = advanced adenoma, CRC = colorectal cancer, “one of two FITs+” = at least one of both FITs
above the cut-off value, “two of two FITs+” = both FITs above the cut-off value, “mean of two FITs+” = geometric mean of both FITs above the cut-off value, CI =
confidence interval, sens = sensitivity, spec = specificity
Oort et al. BMC Cancer 2011, 11:434
http://www.biomedcentral.com/1471-2407/11/434
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for advanced neoplasia for one, two or three FITs did not
differ [19]. In the present study, the full potential of double
FIT sampling was further studied by evaluation of several
definitions of positivity. The present study adds important
information as it is the first to determine if any of three
strategies of double FIT sampling could increase sensitivity
for screen relevant neoplasia, without substantially affect-
ing specificity, at different cut-off values and in a colono-
scopy controlled population.
A limitation of the present study is that not a screening
population was tested but a referral population, partially
containing high risk individuals. Therefore, test charac-
teristics that depend on the prevalence of disease, i.e.
positive and negative predictive values, cannot be gener-
alized from this study to the screening population.
However, the present study focused on sensitivity and
specificity, test characteristics that are not influenced by
t h ep r e v a l e n c eo ft h ed i s e a s e[ 2 5 ] .S t i l l ,i nt h i sr e f e r r a l
population, sensitivity may be overestimated and specifi-
city underestimated due to work-up bias [26]. This may
occur as symptomatic participants have an increased like-
lihood for having both a positive FIT and a colorectal
neoplasm. In particular, it should be noted that lower
sensitivities for FIT in a screening population have been
reported [19,27]. On the other hand, we carried out a for-
mal comparison of FIT results in CRC cases from a
screening and referral cohort and found similar FIT
results after correcting for tumour stage [28]. Since for
screening, only early stage cancers are relevant, in the
present study late stage cancers were excluded from the
analysis. Although possible differences in FIT results
Test characteristics screen relevant neoplasia
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Figure 3 ROC curves of single and double FIT sampling strategies for the detection of screen relevant neoplasia. FIT = faecal
immunochemical test, “one of two FITs+” = at least one of both FITs above the cut-off value, “two of two FITs+” = both FITs above the cut-off value,
“mean of two FITs+” = geometric mean of both FITs above the cut-off value, AUC = area under the curve, CI = confidence interval.
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Page 7 of 10Table 3 Comparison of sensitivity of single and double FIT sampling for screen relevant neoplasia, at fixed specificities
Single FIT “one of two FITs+”“ two of two FITs+”“ mean of two FITs+”
Spec Sens Cut-off Sens Cut-off p-value Sens Cut-off p-value Sens Cut-off p-value
85% 51, 6% 34 53, 2% 59 1 n.a.* n.a.* n.a.* 53, 2% 40 1
90% 46, 0% 73 51, 6% 103 0, 07 44, 4% 27 0, 687 50, 8% 60 0, 125
95% 38, 7% 184 37, 9% 371 1 41, 1% 91 0, 453 37, 9% 159 1
Corresponding cut-off values (ng/ml) and sensitivities for screen relevant neoplasia of single FIT sampling and three different strategies of double FIT sampling at fixed specificities of 85%, 90% and 95%.
FIT = faecal immunochemical test, “one of two FITs+” = at least one of both FITs above the cut-off value, “two of two FITs+” = both FITs above the cut-off value, “mean of two FITs+” = geometric mean of both FITs above
the cut-off value, spec = specificity, sens = sensitivity, cut-off = cut-off value, n.a.* = no corresponding sensitivity and cut-off value found in the range 50-200 ng/ml
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0between referral populations, like in the present study,
and screening populations cannot fully be excluded, the
present study design still allows for comparing the sensi-
tivities of different sampling schemes for FIT for early
stage colorectal cancer. However, a complete correction
of work-up bias cannot be ascertained. One should keep
in mind that alternative study designs also have limita-
tions like absence of a gold standard because no colonos-
copies were performed, or in case colonoscopies were
performed, relatively low numbers of cancers found
[15,16,27]. In addition, in many studies different FITs,
different endpoints (advanced adenoma, advanced neo-
plasia, screen relevant neoplasia), a different amount of
cases, and a different selection of participants (e.g. sub-
jects participating in colonoscopy screening) are used.
To evaluate the effect of work-up bias, analyses were
repeated after exclusion of subjects with rectal blood loss,
anaemia and clinical suspicion of CRC (data not shown).
Although the sensitivities for advanced adenomas found
were 4.5-10% lower, our results were similar in the sense
that double FIT sampling did not yield any superior com-
bination of sensitivity and specificity compared to single
FIT. For CRC data were similar, although too few cases
remained to draw firm conclusions (data not shown).
In the current study the number of excluded partici-
pants was relatively high. This was mainly due to our
stringent protocol on FIT sampling. Of the 251 individuals
that were excluded from further analysis, in the majority
of cases this was because date of sampling was not regis-
tered correctly on the FIT container, as described in the
study protocol. Additional analysis including these cases
showed similar results. The percentage of incomplete
colonoscopies in the present study is in line with previous
studies [7,29].
According to our study protocol all FITs should be
stored in the refrigerator close to the moment of handing
i n .I na d d i t i o n ,b o t hF I T sa r es a m p l e dm a x i m u m7 2
hours prior to colonoscopy. As such, the time that the
tests are at room temperature is kept as limited as possi-
ble. FITs kept at higher temperatures, are more suscepti-
ble to a decrease in sensitivity as a result of haemoglobin
degradation. When compared to at least one of the
screening studies [7] this is still a relative short period of
time. Therefore, only a slight decrease in haemoglobin
concentration is to be expected [30].
An important asset of the present study is the rela-
tively high tumour yield, which allowed analyzing FIT
performance for early and late stage CRC separately. As
the potential health gain is highest for individuals with
early stage cancer [31], this is relevant for population
based screening programs. A second strength of this
study is the fact that colonoscopy results were available
for all participants, allowing the direct calculation of
sensitivities and specificities.
Conclusion
In conclusion, this study strongly suggests that double FIT
sampling, regardless of the definition of test positivity,
does not provide a superior combination of sensitivity and
specificity compared to single FIT sampling. Moreover, if
it is aimed to increase sensitivity at the cost of specificity,
this can be achieved equally well by lowering the cut-off
value of single FIT sampling rather than by double FIT
s a m p l i n g .T ow h a te x t e n tt h e s ef i n d i n g sp e r t a i nt ot h e
general population awaits confirmation in a screening
setting.
Additional material
Additional file 1: Data on colorectal cancer and advanced
adenomas.
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